Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
Market Cap & Net Worth: Allergy Therapeutics plc (AGYTF)
Allergy Therapeutics plc (PINK:AGYTF) has a market capitalization of $614.14 Million ($614.14 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #24406 globally and #8437 in its home market, demonstrating a 92.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Allergy Therapeutics plc's stock price $0.10 by its total outstanding shares 6141439951 (6.14 Billion).
Allergy Therapeutics plc Market Cap History: 2017 to 2025
Allergy Therapeutics plc's market capitalization history from 2017 to 2025. Data shows change from $2.63 Billion to $614.14 Million (-14.21% CAGR).
Allergy Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Allergy Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.13x
Allergy Therapeutics plc's market cap is 8.13 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.63 Billion | $64.14 Million | -$2.48 Million | 40.95x | N/A |
| 2018 | $2.09 Billion | $68.35 Million | -$7.53 Million | 30.55x | N/A |
| 2019 | $1.04 Billion | $73.72 Million | $3.47 Million | 14.16x | 301.14x |
| 2020 | $614.14 Million | $78.20 Million | $7.06 Million | 7.85x | 87.01x |
| 2021 | $2.70 Billion | $84.33 Million | $2.89 Million | 32.04x | 936.32x |
| 2022 | $472.89 Million | $72.77 Million | -$13.78 Million | 6.50x | N/A |
| 2023 | $61.41 Million | $59.59 Million | -$43.07 Million | 1.03x | N/A |
| 2024 | $319.35 Million | $55.20 Million | -$40.22 Million | 5.79x | N/A |
| 2025 | $614.14 Million | $75.56 Million | -$55.09 Million | 8.13x | N/A |
Competitor Companies of AGYTF by Market Capitalization
Companies near Allergy Therapeutics plc in the global market cap rankings as of March 18, 2026.
Key companies related to Allergy Therapeutics plc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Allergy Therapeutics plc Historical Marketcap From 2017 to 2025
Between 2017 and today, Allergy Therapeutics plc's market cap moved from $2.63 Billion to $ 614.14 Million, with a yearly change of -14.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $614.14 Million | +92.31% |
| 2024 | $319.35 Million | +420.00% |
| 2023 | $61.41 Million | -87.01% |
| 2022 | $472.89 Million | -82.50% |
| 2021 | $2.70 Billion | +340.00% |
| 2020 | $614.14 Million | -41.18% |
| 2019 | $1.04 Billion | -50.00% |
| 2018 | $2.09 Billion | -20.51% |
| 2017 | $2.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Allergy Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $614.14 Million USD |
| MoneyControl | $614.14 Million USD |
| MarketWatch | $614.14 Million USD |
| marketcap.company | $614.14 Million USD |
| Reuters | $614.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.